Novo Nordisk’s latest investigational weight loss treatment, CagriSema, has failed to achieve its primary endpoint of demonstrating non-inferiority when compared…
Read More
Lilly is now the top pharma company by revenue as Mounjaro (+99%) and Zepbound (+175%) combine for $36.5B in FY2025
Eli Lilly and Company has officially ascended to the pinnacle of the global pharmaceutical industry, achieving the coveted position of…
Read More
Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk’s investigational triple agonist, UBT251, has demonstrated a mean weight loss of 19.7% after 24 weeks in a Phase…
Read More
Moving beyond the binary: how the convergence of small and large molecules is reshaping pharmaceutical R&D
Pharmaceutical research and development is experiencing a profound transformation, marked by an unprecedented convergence of technological advancements, vast data streams,…
Read More
Pharma 2035 Playbook: Speed, focus and conviction in an uncertain world
The pharmaceutical industry, perpetually at the vanguard of scientific innovation, finds itself navigating an increasingly turbulent global landscape. Characterized by…
Read More
DenovAI’s physics-based bet on one-shot drug design
Rethinking the Drug Discovery Paradigm For decades, the pharmaceutical industry has operated on a well-established, albeit arduous, pipeline: identify "hit"…
Read More
Cellares Raises $257M Series D to Automate Cell Therapy Manufacturing
The burgeoning field of cell and gene therapy, heralded as a revolutionary frontier in medicine, is currently grappling with a…
Read More
TrumpRx.gov: A Federal Portal Faces Scrutiny Amidst Concerns Over Direct-to-Consumer Drug Sales and Patient Safety.
As of early February, the federal portal TrumpRx.gov remains in a nascent state, displaying only a stylized Oval Office portrait…
Read More
The ‘forever drug’ assumption about GLP-1s may be wrong, according to nference analysis
A groundbreaking shift in the understanding of weight management outcomes following the cessation of GLP-1 agonist medications is emerging, challenging…
Read More
Agentic AI-powered literature reviews: Reduce research burdens and accelerate insights
The landscape of scientific research, particularly in drug development and healthcare, is undergoing a profound transformation driven by the advent…
Read More
